Arcadia Biosciences (RKDA) AI Stock Analysis

• Market Cap: $5.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 1.50%
• EPS Growth: -8.01%
• Country: US
• Employees: 9
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): -3.26
• Shares Outstanding: 1,367,040
• 10 Day Avg. Volume: 3,254,407
• 30 Day Avg. Volume: 1,090,692
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 0.70
• Enterprise Value/Ebitda: -0.27
• 1Y Price Target: $12.00
• Price Target Upside: 200.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: $4.00 ▲(0.00% Upside)

Arcadia Biosciences faces significant financial challenges, with declining revenue and ongoing unprofitability being the most impactful factors. The technical analysis suggests some short-term bullish momentum, but the negative valuation metrics, particularly the P/E ratio, weigh heavily on the overall score.

Positive Factors

Low Debt Levels

Arcadia's low debt levels enhance financial flexibility, allowing it to invest in growth opportunities without the burden of high interest obligations.

Strong Equity Position

A strong equity position provides a buffer against financial instability, supporting long-term investment and operational resilience.

Proprietary Technology Platforms

Proprietary technology platforms offer competitive advantages, fostering innovation in product development and enhancing market differentiation.

Negative Factors

Declining Revenue

Declining revenue trends can hinder growth prospects and limit the company's ability to invest in new initiatives, impacting long-term viability.

Unprofitability

Ongoing unprofitability challenges Arcadia's ability to sustain operations and fund future growth, necessitating strategic adjustments to achieve profitability.

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and may limit the company's capacity to invest in growth and innovation, affecting long-term sustainability.

Arcadia Biosciences Business Overview & Revenue Model

Company Description

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

How the Company Makes Money

Arcadia Biosciences generates revenue through a combination of product sales, licensing agreements, and collaborations. The company's key revenue streams include the sale of its innovative crop products, such as its high-fiber wheat and omega-3 soybean products, which are marketed to food manufacturers and agricultural producers. Additionally, Arcadia engages in strategic partnerships with other agricultural companies to co-develop products and technologies, which can include upfront payments, milestone payments, and royalties on future sales. The company's focus on sustainability and nutrition has attracted interest from investors and partners, providing a supportive ecosystem for its revenue generation activities.

Arcadia Biosciences Financial Statement Overview

Summary

Arcadia Biosciences is facing financial challenges, particularly with profitability and cash flow generation. Revenue has declined, and the company remains unprofitable, although it has managed to maintain a strong equity position with minimal debt. The company needs to address its operational efficiency and cash flow management to improve its financial stability.

Income Statement

Arcadia Biosciences has faced challenges in maintaining revenue growth and profitability. The revenue decreased slightly from $5.33 million in 2023 to $5.045 million in 2024, indicating a revenue decline of approximately 5.35%. The gross profit margin improved slightly, but the company remains unprofitable with a negative net income for the year ending 2024. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a debt-to-equity ratio of 0.025, indicating low leverage. However, the return on equity remains negative due to consistent net losses. The equity ratio is 46%, indicating a solid equity position relative to total assets.

Cash Flow

Arcadia Biosciences experienced substantial free cash flow challenges, with negative free cash flow growth. Operating cash flow to net income ratio is negative, reflecting cash flow difficulties. However, cash flow from investing activities was positive, indicating some level of investment recovery.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.26M	5.04M	5.33M	9.96M	6.78M	8.03M
Gross Profit	2.08M	2.08M	2.03M	154.00K	-1.93M	2.83M
EBITDA	-5.47M	-7.50M	-13.58M	-13.65M	-23.27M	-5.44M
Net Income	-2.02M	-7.04M	-13.98M	-15.61M	-16.13M	-6.03M
Balance Sheet
Total Assets	12.99M	13.52M	19.70M	28.92M	43.92M	47.35M
Cash, Cash Equivalents and Short-Term Investments	3.16M	4.24M	11.64M	20.64M	28.68M	25.67M
Total Debt	21.00K	155.00K	1.01M	2.02M	3.29M	9.35M
Total Liabilities	4.08M	7.29M	7.00M	8.02M	12.72M	18.80M
Stockholders Equity	8.90M	6.22M	12.84M	21.03M	31.09M	27.73M
Cash Flow
Free Cash Flow	-8.01M	-9.64M	-15.30M	-14.05M	-26.88M	-32.55M
Operating Cash Flow	-8.01M	-9.63M	-15.29M	-13.98M	-25.87M	-30.22M
Investing Cash Flow	7.84M	7.34M	-4.34M	1.42M	16.61M	17.28M
Financing Cash Flow	9.00K	9.00K	5.51M	4.52M	21.90M	20.56M

Arcadia Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Neutral. The current price of 4 is below the 20-day moving average (MA) of 4.01, above the 50-day MA of 3.82, and below the 200-day MA of 4.08, indicating a bullish trend. The MACD of 0.16 indicates Positive momentum. The RSI at 50.83 is Neutral, neither overbought nor oversold. The STOCH value of 27.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RKDA.

Arcadia Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BIOX	―	$115.39M	-2.44	―	―	-28.28%	-1718.93%
BHST	―	$225.52M	―	-973.22%	―	57.83%	40.94%
RKDA	―	$5.60M	-0.72	-87.18%	―	1.50%	-8.01%
SEED	―	$12.89M	-30.12	―	―	-21.82%	-104.92%
LVRO	―	$171.75M	―	―	―	―	―
AVD	―	$152.11M	―	-42.97%	―	-9.57%	-3226.39%

Arcadia Biosciences Corporate Events

Arcadia Biosciences Announces 2025 Annual Meeting Date

Arcadia Biosciences, Inc. has announced that its 2025 annual meeting of stockholders will be held on December 19, 2025. The company has also informed stockholders of a change in the meeting date and updated deadlines for submitting proposals and nominations for the meeting. This announcement follows a Securities Exchange Agreement with Roosevelt Resources, LP, which involves an all-stock transaction for the combination of the two companies. The meeting and the proxy statement are separate from the special meeting related to this transaction.

The most recent analyst rating on (RKDA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.

Arcadia Biosciences CFO Resignation Announced

On August 26, 2025, Arcadia Biosciences‘ CFO, Mark Kawakami, announced his resignation effective September 12, 2025, with no disagreements cited as the reason. Thomas J. Schaefer, the company’s President and CEO, will assume the role of Interim CFO. Additionally, Arcadia is involved in a proposed all-stock transaction with Roosevelt Resources, with plans to issue shares in exchange for Roosevelt’s equity interests, pending regulatory approvals.

The most recent analyst rating on (RKDA) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.

Arcadia Biosciences Reports Revenue Growth Amid Challenges

Arcadia Biosciences, Inc. is a company focused on producing and marketing innovative wellness products, primarily in the agricultural sector, known for its high-value, healthy ingredients. In its recent earnings report, Arcadia Biosciences announced an 11% increase in total revenues year-over-year, driven by a significant 24% growth in its Zola coconut water brand. The company also reported receiving 2.7 million shares of stock in Above Food Ingredients Inc. and eliminating $1 million in liabilities. Key financial highlights include a 16% increase in revenues for the first half of 2025 compared to the same period in 2024, with Zola coconut water sales showing a 47% increase. Despite these positive developments, Arcadia reported a net loss attributable to common stockholders of $4.5 million for the second quarter of 2025, primarily due to a $4.5 million credit loss related to a note receivable from Above Food. Looking ahead, Arcadia Biosciences remains focused on its pending business combination with Roosevelt Resources, aiming to strengthen its market position and continue its growth trajectory.